MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. - Wikidata - wikimedia - TriplyDB

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

http://www.wikidata.org/entity/Q35028389

about

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Myeloid suppressor cells and immune modulation in lung cancer Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications Regulation of tumor metastasis by myeloid-derived suppressor cells Circulating biomarkers in advanced renal cell carcinoma: clinical applications Improving cancer immunotherapy by targeting the STATe of MDSCs Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease.A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.Complexity and challenges in defining myeloid-derived suppressor cells Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Intravascular staining for discrimination of vascular and tissue leukocytes.Myeloid derived suppressor cells in chronic myeloid leukemia.Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Macrophage Migration Inhibitory Factor Secretion Is Induced by Ionizing Radiation and Oxidative Stress in Cancer Cells.A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment.Transcriptional regulation of myeloid-derived suppressor cells.Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.Contrasting effects of sunitinib within in vivo models of metastasis.Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories.The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.

P2860

Q26744395-06538A0D-6C55-4114-B107-74A1D3CEC15A Q26823035-DF805C02-7D94-46AF-B9EC-18ADC81547E2 Q26823251-D0A57C7D-0920-4F4E-899C-519EA111080B Q26852437-F3B0470A-872E-432A-83E7-5161A13AF516 Q26863418-D5C4293D-3F6E-4A9A-9532-DE60D827701A Q27014189-4BE051E0-12FB-4853-9871-344DB00A7A3F Q27022125-D86FD6B7-BB28-44E4-AC18-5D6703632EDF Q27023770-964844BF-08DE-48F9-9A27-98F0F78CAF54 Q28066797-7BD432E8-5273-4287-9912-02AAFC54A416 Q28084627-EA02036E-5250-4236-919B-05EDEF31B137 Q30317831-EE9AE241-0EBB-48F4-B99E-C17AFBC2B833 Q33564156-E0171A51-AC18-45C9-92C1-4C3CC4FAB561 Q33592056-2A5E550C-FB3E-440F-A084-13DD1D4DA5AF Q33889439-494A2434-6C9F-4A1A-9ACC-226688728E19 Q33996767-6AA89F82-7B81-4A4F-8273-70BD604B77FC Q34502899-72F0D51C-82B3-4B76-B88E-D9B163DF1D22 Q34517267-0F195402-7FFF-4B89-BECA-DC43A9263179 Q34570094-CCA87F49-F10B-4EF3-8638-028D3A15C050 Q35506659-C17E9C37-29A1-4B42-908E-5CC8B7559869 Q35509317-C4B46DEA-511D-40F3-8890-91B5506CE10E Q35534962-B6B77425-FE16-4F85-903D-F7AFBC2E1884 Q35578622-CB26C2DC-82DE-426A-B193-6E97DA5B7A37 Q35596407-B718700E-6A79-4BE7-AC79-AEDCDFC57A5F Q35609094-2F4F08BC-6819-473A-8850-1EBFDA1CEBEF Q35675548-2F98AFBD-4672-43F6-A6F0-371FC50BC9EA Q35887319-10E41812-DDB0-4072-99ED-60361C023FBC Q35888073-CF581933-D517-4F25-A4FD-C7990AA469D8 Q36107975-F9798DFB-8F83-458E-BB7B-5036D40A1853 Q36108579-19994C42-A20E-4EF7-A795-7AD1158DB1D9 Q36242193-B1BEE2C9-CAC7-4C05-9170-281811B518B8 Q36322351-BF2FF841-C55B-4474-91DB-5C7B0A0988EB Q36335477-08B9F379-A8E5-4D91-AB97-630D0CA1AF6F Q36394262-40F2C283-F651-4A1C-B8F4-712E81B7081B Q36483105-38860204-2851-4D69-98CE-6FF168822B92 Q36489379-10D63ACD-20F6-40A1-9F61-847DBD4A3647 Q36572163-1B9DC4D2-69CE-491A-A831-C02F381E21EA Q36587186-96C8296C-3382-4C92-AB83-CA735330B80B Q36685551-70226EA7-7D1D-48ED-9FB9-069E222B0FF8 Q36918248-178ABDED-CF81-4FD1-A937-A2E0483A9509 Q36938866-BD7795D2-F142-4663-B8B4-C7144468B108

P2860

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

http://www.wikidata.org/entity/Q35028389

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@ast

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@en

type

label

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@ast

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@en

prefLabel

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@ast

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@en

P1433

Q35028389-41337787-BC9B-447B-B1ED-9D8F70F783AC

P1476

Q35028389-162B9E73-B533-4382-839F-0100A3CE4710

P2093

Q35028389-1D2D2A64-5518-4FA5-8777-E63A435DEC0C

Q35028389-83F061CC-6A6E-4AA4-8A5E-965E8C0E72C0

Q35028389-9CC4E354-85B5-4993-B0BF-927D863AFACA

Q35028389-C9F67EA7-DD8A-4609-B0D4-1AD074EE16EC

Q35028389-DB3F76B2-434F-420D-886C-1A25600AD384

Q35028389-E9528F2E-A8AC-4277-AE43-30B5430A61F1

P2860

Q35028389-00416FF4-0259-40A6-B673-330DC2B0C69E

Q35028389-04945862-19D6-445F-8D57-F0E3FB7700E5

Q35028389-0C587C1A-4469-4AE5-AB47-BAD2AD5BC937

Q35028389-102C3989-2E51-4AFB-98A5-3E17229E679F

Q35028389-140A2837-DB88-44A9-99C4-FEE8A7489100

Q35028389-157CA5E7-A29D-48DB-96A3-60B5306839C7

Q35028389-28D28908-B4A7-4180-850A-BFAB1F0A3DD8

Q35028389-2B8DDE3C-D05B-4E72-B497-8367D0A7226F

Q35028389-34D9C4BD-EB2D-48D5-8228-5857D14255C3

Q35028389-3FC4EC43-B12E-4364-BA42-32890C35C820

P304

Q35028389-BD2E9C4C-2AEB-46CB-A72F-2241C5658D75

P31

Q35028389-064ED78A-9505-4B2A-82B7-C776202AE3FE

P356

Q35028389-23362485-6D9F-4705-AA2E-FB7A98545373

P433

Q35028389-7A0E0DC2-276A-4E7C-AF95-95C4529994BE

P478

Q35028389-E311110A-E3BD-4AAC-884E-71138EA171E0

P577

Q35028389-BD3738BC-E080-443F-8E16-4C012BFAAEFC

P5875

Q35028389-158FC97C-9991-427E-8C0A-04100E2E0FC5

P698

Q35028389-8A63CA8E-49DF-47E9-8138-1D96430F5041

P932

Q35028389-E16B9A6A-6666-4026-B3C2-D693E8F04A1E

P356

J.INTIMP.2011.01.030

P1433

International Immunopharmacology

P1476

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

@en

P2093

Brian Rini

http://www.w3.org/2001/XMLSchema#string

James Finke

http://www.w3.org/2001/XMLSchema#string

Jennifer Ko

http://www.w3.org/2001/XMLSchema#string

Joanna Ireland

http://www.w3.org/2001/XMLSchema#string

Pat Rayman

http://www.w3.org/2001/XMLSchema#string

Peter Cohen

http://www.w3.org/2001/XMLSchema#string

P2860

Myeloid-derived suppressor cells as regulators of the immune system

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Mechanisms and functional significance of tumour-induced dendritic-cell defects.

P304

856-861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.INTIMP.2011.01.030

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49830934

http://www.w3.org/2001/XMLSchema#string

P698

21315783

http://www.w3.org/2001/XMLSchema#string

P932

3109226

http://www.w3.org/2001/XMLSchema#string